Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01818739 · ClinicalTrials.gov registry record · NA

Lymph Node Mapping in Patients With Endometrial Cancer

A NA study of Endometrial Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
204
Enrollment target
2
Study locations

NCT01818739: Completed NA study of Endometrial Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

NCT01818739 is a NA study of Endometrial Cancer that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 204 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01818739, a NA study of Endometrial Cancer, has completed, sponsored by Ohio State University Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
204 participants
Enrollment target
2
Study locations

Study Summary

This clinical trial studies lymph node mapping in patients with endometrial cancer. Lymph node mapping may allow for limited removal of lymph nodes in as part of endometrial cancer staging and treatment.

Primary Outcome

NPV is found by dividing the number of true negatives by the number of all patients without pelvic lymph node metastases. Exact 95% confidence intervals (CIs) for the proportions will be calculated.

Conditions Studied

Interventions

  • PROCEDURE sentinel lymph node biopsy
  • DRUG indocyanine green solution
  • PROCEDURE sentinel lymph node detection
  • DRUG isosulfan blue

Study Locations (2)

Connecticut

  • Smilow Cancer Hospital at Yale New Haven - New Haven

Ohio

  • Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center - Columbus

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2013-03
Est. Completion 2017-03-31
Phase NA

What the finished NCT01818739 record still lists

NCT01818739 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 4 interventions - of which sentinel lymph node biopsy is the first listed.

NCT01818739 reports a single indexed study location in Connecticut, Ohio.

Frequently Asked Questions

What is clinical trial NCT01818739 about?

NCT01818739 is a clinical study titled "Lymph Node Mapping in Patients With Endometrial Cancer". This clinical trial studies lymph node mapping in patients with endometrial cancer. Lymph node mapping may allow for limited removal of lymph nodes in as part of endometrial cancer staging and treatment.

What is the current status of trial NCT01818739?

This trial is currently completed. It is a NA study. The enrollment target is 204 participants. The study started on 2013-03. Estimated completion is 2017-03-31.

What conditions does trial NCT01818739 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT01818739?

The interventions under investigation include: sentinel lymph node biopsy (PROCEDURE), indocyanine green solution (DRUG), sentinel lymph node detection (PROCEDURE), isosulfan blue (DRUG).

Who is sponsoring clinical trial NCT01818739?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01818739 being conducted?

This trial has 2 study locations across Connecticut, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01818739's enrollment target sits among peer trials

204 69th of 181 higher than 113 of 181 other Endometrial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03481010 · 204 participants · NA

    Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

  • NCT04249830 · 204 participants · NA

    Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

  • NCT04503395 · 204 participants · NA

    ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

  • NCT04793776 · 204 participants · NA

    Manage Emotions to Reduce Aggression (MERA)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01818739, the US trial registry maintained by the National Library of Medicine. NCT01818739 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.